CORESTEMCHEMON Inc.
KKRX:1664801,690.00
KRW
+18.00
(+1.08%)
ISIN
KR7166480004
Return %
Stock
S&P 500
1Y
-5.11
14.20
3Y
-61.69
81.12
5Y
-88.97
68.34
Capital Structure
KRW
•
in mil. unless spec.Working Capital
KRW
•
in mil. unless spec.Growth Rates
KRW
•
in mil. unless spec.Quarterly Revenue
KRW
•
in mil. unless spec.Quarterly Earnings Per Share
KRW
•
in mil. unless spec.Quarterly Dividends Per Share
KRW
•
in mil. unless spec.Company Description
- CEO
- Gil-Ahn Yang
- Full Time Employees
- 321
- Sector
- Health technology
- Industry
- Pharmaceuticals: major
- Address
- Seongnam-si South Korea
- IPO Date
- Jun 26, 2015
- Website
- corestemchemon.com
- Similar Companies
- Business
- CORESTEMCHEMON Inc. is a South Korea-based biotechnology and non-clinical contract research organization specializing in the research, development, and commercialization of autologous stem cell therapeutics and comprehensive preclinical drug testing services. The company operates through two core business divisions: Biopharmaceuticals and Non-Clinical Contract Research Services. In its Biopharmaceuticals division, the company manufactures and develops regenerative cell therapies, highlighted by its commercialized flagship product, NeuroNata-R, an autologous bone marrow-derived mesenchymal stem cell treatment approved for Amyotrophic Lateral Sclerosis; an investigational pipeline of stem cell therapeutics targeting intractable neurological and autoimmune disorders, including cerebellar ataxia, systemic lupus erythematosus, multiple system atrophy, and osteoarthritis; and specialized Good Manufacturing Practice-compliant cell processing and banking operations. In its Non-Clinical Contract Research division, the company provides Good Laboratory Practice-accredited preclinical evaluation services to pharmaceutical, biotechnology, medical device, cosmetic, and chemical organizations, encompassing general and specialized in vivo and in vitro toxicology studies; safety pharmacology testing; genetic, reproductive, developmental, and carcinogenicity assessments; pharmacokinetic, toxicokinetic, and absorption, distribution, metabolism, and excretion profiling; in vivo efficacy screening across oncology, central nervous system, and metabolic disease models; and medical device biocompatibility evaluations in compliance with international standards. Founded in 2003 and headquartered in Seongnam-si, Gyeonggi-do, South Korea, CORESTEMCHEMON Inc. serves biopharmaceutical developers, research institutes, and healthcare corporations across South Korea, North America, and the broader Asia-Pacific region. In recent developments, the company executed a corporate merger between stem cell developer Corestem Inc. and non-clinical contract research provider Chemon Inc. to establish CORESTEMCHEMON Inc., integrating therapeutic research and development with commercial contract testing capabilities. The company has actively advanced its multi-center Phase 3 clinical trial of NeuroNata-R across sites in the United States and South Korea under U.S. Food and Drug Administration protocols, bolstered by orphan drug and fast track designations. Furthermore, CORESTEMCHEMON Inc. has expanded its Good Laboratory Practice testing facilities and laboratory capacities to accommodate growing demand for advanced biopharmaceutical and gene therapy preclinical evaluations, while entering into strategic co-development and testing partnerships with international life sciences enterprises.